Management of Hot Flashes

Introduction to Hot Flash Management

For most women experiencing hot flashes, non-hormonal medications such as venlafaxine, gabapentin, or paroxetine should be used as first-line pharmacological treatment due to their proven efficacy and favorable safety profiles, as recommended by the National Comprehensive Cancer Network and the American Cancer Society 1, 2

Venlafaxine (SNRI) reduces hot flash frequency and severity by 40-60%, with side effects including dry mouth, reduced appetite, nausea, and constipation, and is preferred over SSRIs for women with a history of breast cancer or those taking tamoxifen 1
Paroxetine (SSRI) reduces hot flash frequency by 40-50% and severity by 45-65%, but should be avoided in women taking tamoxifen as it may reduce tamoxifen's effectiveness by inhibiting CYP2D6 enzyme, according to the American Cancer Society 1, 2
Gabapentin reduces hot flash severity by 46-49% at a dose of 900 mg daily, with side effects including somnolence and fatigue, and is a good alternative for women with a history of breast cancer or those taking tamoxifen 1

Women with a history of breast cancer or those taking tamoxifen should avoid estrogen-containing products, as they may increase cancer recurrence risk, and avoid paroxetine and fluoxetine due to drug interactions, as recommended by the National Comprehensive Cancer Network and the American Cancer Society 1, 2
Clonidine (oral or transdermal) reduces hot flashes in a dose-dependent manner, with side effects including dry mouth, constipation, and drowsiness 1

Before or alongside medication, consider weight loss if overweight, smoking cessation, limiting alcohol intake, regular physical activity, and cognitive behavioral therapy, as recommended by the American Cancer Society 3
Environmental modifications, such as cool rooms and dressing in layers, can also help reduce hot flashes, according to the American Cancer Society 2

Assess severity and impact on quality of life, and try non-pharmacological approaches first for mild symptoms, as recommended by the National Comprehensive Cancer Network 1
Rule out contraindications, such as history of breast/uterine cancer or taking tamoxifen, and select appropriate medication based on individual patient needs, according to the American Cancer Society 1, 2
Titrate dose based on response, starting with the lowest effective dose and increasing if needed after 1-4 weeks, and continue for the shortest duration needed to control symptoms, as recommended by the National Comprehensive Cancer Network 1
Monitor for side effects and efficacy, reassessing at 4-8 weeks and considering switching medication if inadequate response or intolerable side effects, according to the American Cancer Society 1, 2